Model‐Based Drug–Drug Interaction Extrapolation Strategy From Adults to Children: Risdiplam in Pediatric Patients With Spinal Muscular Atrophy

Risdiplam (Evrysdi) improves motor neuron function in patients with spinal muscular atrophy (SMA) and has been approved for the treatment of patients ≥2 months old. Risdiplam exhibits time‐dependent inhibition of cytochrome P450 (CYP) 3A in vitro. While many pediatric patients receive risdiplam, a d...

Descripción completa

Detalles Bibliográficos
Autores principales: Cleary, Yumi, Gertz, Michael, Grimsey, Paul, Günther, Andreas, Heinig, Katja, Ogungbenro, Kayode, Aarons, Leon, Galetin, Aleksandra, Kletzl, Heidemarie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9291816/
https://www.ncbi.nlm.nih.gov/pubmed/34347881
http://dx.doi.org/10.1002/cpt.2384

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9291816/
https://www.ncbi.nlm.nih.gov/pubmed/34347881
http://dx.doi.org/10.1002/cpt.2384

Ejemplares similares